Mirabegron(meer’ ah beg’ ron)
Myrbetriq
PREGNANCY CATEGORY C
Drug Classes
Beta3-adrenergic agonist
Bladder antispasmodic
Therapeutic Actions
Relatively selective agonist of beta3 adrenergic receptors. Stimulating these receptors relaxes the detrusor smooth muscle during the storage phase of bladder filling, which increases bladder capacity.
Indications
Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Contraindications and Cautions
Contraindicated with history of serious hypersensitivity to components of drug, severe uncontrolled hypertension, lactation.
Use cautiously with bladder outlet obstruction, hypertension, renal or hepatic impairment pregnancy.
Available Forms
ER tablets—25, 50 mg
Dosages
Adults
25 mg/day PO; may increase to 50 mg/day PO after 8 wk if needed.
Patients with severe renal or moderate hepatic impairment
Do not exceed 25 mg/day.
Patients with end-stage renal disease or severe hepatic impairment
Not recommended.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
